


# Anthropogenic Trace Pollutants in the Water Cycle

## Pharmaceuticals

May 2008





# **Anthropogenic Trace Pollutants in the Water Cycle**

## **Pharmaceuticals**

May 2008



Publisher/Marketing:  
Deutsche Vereinigung für Wasserwirtschaft, Abwasser und Abfall e. V.  
German Association for Water, Wastewater and Waste  
Theodor-Heuss-Allee 17 · 53773 Hennef · Germany  
Tel.: +49 2242 872-333 · Fax: +49 2242 872-100  
E-Mail: [kundenzentrum@dwa.de](mailto:kundenzentrum@dwa.de) · Internet: [www.dwa.de](http://www.dwa.de)

# **Anthropogenic Trace Pollutants in the Water Cycle**

---

The German Association for Water, Wastewater and Waste (DWA) is intensively involved with the development of reliable and sustainable water management. Being a politically and economically independent organisation it operates specifically in the areas of water management, wastewater, waste and soil protection.

In Europe the DWA is the association in this field with the greatest number of members and, due to its specialist competence, it holds a special position with regard to standardisation, professional training and information of the public. The members, approximately 14,000 represent specialists and managers from municipalities, universities, consulting engineers, authorities and businesses.

## **Imprint**

### **Published and sold by:**

DWA German Association for  
Water, Wastewater and Waste  
Theodor-Heuss-Allee 17  
53773 Hennef, Germany  
Tel.: +49 2242 872-333  
Fax: +49 2242 872-100  
E-Mail: [kundenzentrum@dwa.de](mailto:kundenzentrum@dwa.de)  
Internet: [www.dwa.de](http://www.dwa.de)

### **Translation:**

CLAUDIA MAYERL, Braunschweig

### **Printing (English version):**

BUB Bonner Universitätsbuchdruckerei

### **ISBN:**

978-3-941089-51-8

The translation was sponsored by the LIFE+ programme, the EU's funding instrument for the environment 2007–2013

Printed on 100 % recycled paper

© DWA Deutsche Vereinigung für Wasserwirtschaft, Abwasser und Abfall e. V., Hennef 2009  
(German Association for Water, Wastewater and Waste)

All rights, in particular those of translation into other languages, are reserved. No part of this publication may be reproduced in any form – by photocopy, microfilm or any other process – or transferred into a language usable in machines, in particular data processing machines, without the written approval of the publisher.

## **Foreword**

This issue of DWA Topics has been elaborated by the DWA Working Group KA-8.1 "Anthropogenic Trace Pollutants in the Water Cycle" and Committee III "Basic Research" of the Waterchemical Society. The DWA-Working Group would like to thank DWA and DVGW members for numerous valuable comments and critical remarks.

This issue of DWA Topics primarily addresses representatives from politics and administration as well as from public utilities, but also producers, consumers and users of products, which contain anthropogenic trace pollutants. Generally, anthropogenic trace pollutants include organic compounds such as pharmaceuticals, personal care products, perfluorinated compounds, pesticides or biocides, which can be detected in wastewater, groundwater, surface waters or drinking water in ranges of  $\mu\text{g/L}$  to  $\text{ng/L}$ .

Using pharmaceuticals as an example, this issue of DWA-Topics discusses the current pollution load and explores the complex problem of anthropogenic trace pollutants, ecotoxicological and human-toxicological risks as well as possible consequences for water supply and wastewater disposal. An interdisciplinary approach was used to look at the problem from the point of view of human-toxicology, ecotoxicology, environmental and water chemistry as well as wastewater treatment and drinking water supply. The objective of this publication is to present risk potentials, to recommend possible activities at various levels and to point out loopholes in national and European law.

An easy standard solution for the avoidance and/or removal of anthropogenic pollutants from the urban water cycle does not exist. Politicians/administration, producers, users, consumers as well as public utilities must cooperate in the future, in order to minimize risks, which may result from the pollution of surface waters, groundwaters and drinking waters.

After an introduction to the problem (Chapter 1), Chapter 2 exemplarily describes pollution caused by selected pharmaceuticals in various environmental matrices such as wastewater, flowing water bodies and drinking water. Chapter 3 discusses deficits of the German Drinking Water ordinance in regard to anthropogenic trace pollutants and recommends solutions for these deficits. Measures to reduce discharge of pharmaceuticals are discussed in Chapter 4. In Chapter 5, new legal regulations for assessing ecotoxicological risks of pharmaceuticals are introduced. Chapters 6 and 7 describe processes for the elimination of pharmaceutical residues and other trace pollutants during wastewater and drinking water treatment. Afterwards in Chapter 8, the occurrence of anthropogenic trace pollutants in drinking water is discussed in regard to legal regulations and aesthetic aspects. Chapter 9 gives scientific background and regulatory aspects for an assessment from the point of view of ecotoxicology. Examples of international water reuse projects can be found in Chapter 10. Finally, Chapter 11 presents problems of closed urban water cycles using the example of the city of Berlin, while Chapter 12 describes agricultural water reuse in Braunschweig, Germany. Based on the information given in the previous chapters, Chapter 13 shows current demand for further research.

It is not the objective of this DWA Topics to give a complete survey of literature existing on the topic of trace pollutants in the water cycle. Wherever necessary, suggestions for further readings are given.

## **Authors**

This issue of DWA Topics was elaborated by the DWA-Working Group KA-8.1 "Anthropogenic Trace pollutants in the Water Cycle" within the DWA-Committee KA-8 "Processes for advanced wastewater treatment after biological treatment". The DWA-Working Group KA-8.1 has the same members as the Committee III "Basic Research" of the Waterchemical Society – a Division of the German Chemical Society.

The DWA-Working Group KA-8.1 "Anthropogenic Trace pollutants in the Water Cycle" has the following members:

BAUER, Karl-Heinz	Dr., Hessenwasser GmbH & Co. KG, Groß-Gerau
DIETER, Hermann	PD. Dr., UBA, Berlin
DÜNNBIER, Uwe	Dr., Berliner Wasserbetriebe
GEIßEN, Sven-Uwe	Prof. Dr.-Ing., TU Berlin
GRUMMT, Tamara	Dr., UBA, Bad Elster
KNACKER, Thomas	Dr., ECT, Flörsheim
MÜCKTER, Harald	PD Dr., Ludwig-Maximilians-Universität, München
SEEL, Peter	Dr., Hessisches Landesamt für Umwelt und Geologie, Wiesbaden
SIEGRIST, Hansruedi	Prof. Dr., EAWAG, Duebendorf/Schweiz
SCHWARTZ, Thomas	Dr., Forschungszentrum Karlsruhe
TEISER, Bernhard	Dipl.-Ing., Abwasserverband Braunschweig
TERNES, Thomas	PD Dr., BfG, Koblenz (spokesperson of the Working Group)
WEBER, Lilo	Dipl.-Ing., Hessenwasser GmbH & Co. KG, Groß-Gerau

Project organizer within the DWA Head Office:

THALER, Sabine	Dipl.-Biol., Hennef (Department Wastewater and Water Protection)
----------------	---

## Contents

<b>Foreword</b> .....	<b>3</b>
<b>Authors</b> .....	<b>4</b>
<b>List of Figures</b> .....	<b>7</b>
<b>List of Tables</b> .....	<b>8</b>
<b>Argumentation and Summarizing Discussion</b> .....	<b>9</b>
Intention of this Issue of DWA-Topics .....	9
Concluding Discussion and Requirements for Politics, Science and Associations .....	9
<b>1 Introduction</b> .....	<b>13</b>
1.1 Sanitary Engineering and Wastewater Reuse .....	13
1.2 Pathways of Pharmaceuticals to the Environment.....	15
<b>References</b> .....	<b>16</b>
<b>2 Contamination Situation in Regard to Pharmaceuticals</b> .....	<b>17</b>
2.1 Introduction .....	17
2.2 Treated Wastewater and Flowing Water Bodies .....	17
2.3 Groundwater and Drinking Water .....	19
2.4 Other Environmental Matrices .....	20
2.5 Pathogenic Microorganisms as Carriers of Antibiotic Resistances .....	20
<b>References</b> .....	<b>22</b>
<b>3 Evaluation of Surface Water Contamination within the Enforcement of the European Water Framework Directive (WFD)</b> .....	<b>25</b>
<b>4 Strategies for Preventing Discharge of Pharmaceuticals into Water Bodies</b> .....	<b>27</b>
4.1 Introduction of an Ecolabel .....	28
4.2 Treatment of Highly Polluted Waste Streams and Source Separation .....	29
4.3 Example: Iodinated X-Ray Contrast Media.....	30
4.4 Conclusion .....	31
<b>References</b> .....	<b>32</b>
<b>5 Considering Environmental Fate and Effects of Pharmaceuticals During Market Approval</b> .....	<b>33</b>
5.1 Environmental Risk Assessment for Individual Substances .....	33
5.2 Examples .....	34
5.3 Outlook .....	38
<b>References</b> .....	<b>38</b>
<b>6 Removal Mechanisms in Mechanical-Biological Wastewater Treatment Plants and Possible Advanced Treatment Procedures</b> .....	<b>40</b>
6.1 Introduction .....	40
6.2 Sorption .....	41
6.3 Biological Degradation .....	42
6.4 Advanced Measures for Municipal Wastewater Treatment.....	44
6.5 Conclusion .....	47
<b>References</b> .....	<b>48</b>

# **Anthropogenic Trace Pollutants in the Water Cycle**

---

<b>7</b>	<b>Requirements for Drinking Water Treatment</b> .....	<b>49</b>
7.1	Introduction .....	49
7.2	Processes for Drinking Water Treatment.....	50
7.3	Removal Efficiency of Selected Treatment Processes in Regard to Pharmaceuticals .....	50
7.4	Examples of Process Combinations for Drinking Water Treatment of Surface Waters with a Wastewater Influence .....	57
7.5	Discussion and Outlook .....	58
	<b>References</b> .....	<b>58</b>
<b>8</b>	<b>Evaluation of Pollution of Drinking Water with Mobile Organic (and Inorganic) Contaminants in View of Drinking Water Hygiene and Aesthetics</b> .....	<b>61</b>
8.1	Evaluation of Drinking Water Hygiene .....	61
8.2	Aesthetic Evaluation – How Much Recycling Can be Handled, How Much Is Obligatory? .....	62
	<b>References</b> .....	<b>63</b>
<b>9</b>	<b>Human Toxicity of Pharmaceuticals/Combined Effects in the Aquatic Environment</b> ....	<b>64</b>
9.1	Introduction .....	64
9.2	Substances of Special Interest for Public Health .....	64
9.3	Toxicological Data and Their Interpretation .....	65
9.4	Kinetic Data .....	66
9.5	Regulatory Aspects .....	66
9.6	Health Risk Assessment .....	66
9.7	Precautionary Principle, Prioritization (HPV, TTC) .....	67
9.8	Combination Toxicology: Definition and Problems .....	68
9.9	Conclusion .....	68
	<b>References</b> .....	<b>69</b>
<b>10</b>	<b>Wastewater Reuse</b> .....	<b>70</b>
10.1	Introduction .....	70
10.2	International Examples.....	71
	<b>References</b> .....	<b>74</b>
<b>11</b>	<b>Sources and Collectors of Anthropogenic Pollutants in the Berlin Water Cycle</b> .....	<b>75</b>
	<b>References</b> .....	<b>78</b>
<b>12</b>	<b>Water Reuse in Braunschweig</b> .....	<b>79</b>
	<b>References</b> .....	<b>81</b>
<b>13</b>	<b>Demand for Research and Measures</b> .....	<b>82</b>
	<b>Glossary</b> .....	<b>83</b>
	<b>Abbreviations and Symbols</b> (not part of the German version).....	<b>85</b>

## List of Figures

Figure 1.1:	Pollutants, which have been monitored for a long period of time and have already been regulated to a large extent .....	13
Figure 1.2:	Selection of emerging contaminants which have been detected in flowing water bodies in the last couple of years and have been gaining in importance .....	14
Figure 1.3:	Pathways of pharmaceuticals to environment and potable water .....	16
Figure 2.1:	Schematic presentation of drug metabolism .....	17
Figure 2.2:	Comparison of contamination of small streams located in Hessisches Ried/Germany and the large rivers Rhine and Main with selected .....	19
Figure 2.3:	Concentrations of four selected pharmaceuticals in exposed groundwaters .....	20
Figure 3.1:	Schematic presentation of risk assessment for water bodies according to the WFD .....	25
Figure 4.1:	Options for reducing discharge of pharmaceuticals at their source .....	28
Figure 4.2:	Decentralized wastewater treatment concept of the Hans Huber AG .....	30
Figure 5.1:	Simplified schematic presentation of the steps of an environmental risk assessment for declaration and registration of individual substances .....	34
Figure 5.2:	Schematic presentation of the steps of an environmental risk assessment according to EMEA (2006) for 17 $\alpha$ -ethinyl estradiol (EE2) .....	36
Figure 5.3:	Schematic presentation of the steps of an environmental risk assessment according to EMEA (2006) for carbamazepine (CBZ) .....	37
Figure 6.1:	Historical development of the activated sludge treatment .....	40
Figure 6.2:	Sorption constant and sorbed fraction of selected compounds in the influent as well as in primary and secondary sludge .....	42
Figure 6.3:	Biological degradation or transformation of a compound in dependency on sludge age ( $t_{DS}$ ) of the activated sludge .....	43
Figure 6.4:	Substance flow and degradation of the contraceptive 17 $\alpha$ -ethinyl estradiol at the wastewater treatment plant at Wiesbaden, Germany in g per day. ....	44
Figure 6.5:	Oxidation of pharmaceuticals in biologically treated wastewater by treatment with ozone .....	46
Figure 7.1:	Water resources and frequently used treatment processes .....	50
Figure 7.2:	Break through behaviour of diatrizoat and iopromid during activated carbon filtration (F300) at waterworks .....	54
Figure 7.3:	Half-lives and reaction rate constants for the reaction of pharmaceuticals with ozone .....	55
Figure 7.4:	Retention of substances using membrane processes .....	56
Figure 7.5:	Removal of selected pharmaceuticals during treatment at a German waterworks .....	57
Figure 7.6:	Removal of ICM during surface water treatment O <sub>3</sub> -dosage pre-ozonation: 1 mg/l; dosage main ozonation: 1.7 mg/l; spec. throughput of the activated carbon filters 30 to 72 m <sup>3</sup> /kg .....	57
Figure 10.1:	Water sources and water supply in Windhoek, Namibia .....	71
Figure 10.2:	Direct water reuse in Windhoek, Namibia .....	72
Figure 10.3:	Water Factory 21 .....	72
Figure 10.4:	NEWater, Singapore .....	73
Figure 11.1:	Hydrogeological view of the city of Berlin .....	75
Figure 11.2:	Origin of raw water used for drinking water production in Berlin .....	76
Figure 11.3:	Technical parts of the water system of the Berliner Wasserbetriebe .....	76
Figure 11.4:	Water cycle in the urban area of Berlin .....	78
Figure 12.1:	Water Reuse concept of the city of Braunschweig .....	79



## List of Tables

Table 2.1:	Concentration ranges of detected pharmaceuticals in German WWTP effluents .....	18
Table 2.2:	Concentration ranges of detected pharmaceuticals in German rivers and streams .....	18
Table 4.1:	Evaluation of removal efficiency of a pharmaceutical due to flocculation, ozonation and activated carbon filtration .....	29
Table 5.1:	Characteristics of selected pharmaceuticals.....	35
Table 5.2:	Predicted concentrations of two pharmaceuticals for human use (CBZ and EE2) in surface waters in Germany ( $PEC_{sw-G}$ ), calculated according to equation 1, in which however $DOSE_{ai}$ has been replaced by defined daily dose values (DDD) of the WHO (2005); refined values of $PEC_{sw-G}$ according to EMEA-guideline; comparison with measured concentrations ( $MEC_{sw-G}$ ); compiled and evaluated according to LIEBIG et al. (2006) .....	35
Table 6.1:	Concentration and removal (in brackets) of pharmaceuticals (LOD: 0.050 µg/L) and estrone (LOD: 3 ng/L) in the wastewater treatment plant effluent of Braunschweig, Germany (DOC: 23.0 mg/L, pH 7.2) before/after ozonation (5, 10, 15 mg/L $O_3$ ) .....	45
Table 6.2:	Number of resistances detected in enterococci from the urban and rural influent of a WWTP and after dosing of 8 resp. 15 g ozone per m <sup>3</sup> WWTP effluent of biologically treated wastewater .....	46
Table 7.1:	Efficiency of bank filtration, flocculation and activated carbon filtration for the removal of pharmaceuticals.....	51
Table 7.2:	Efficiency of advanced treatment processes for the removal of pharmaceuticals .....	52
Table 9.1:	Ranking of the five most prescribed classes of pharmaceuticals with exemplary substances detected in the water cycle .....	64
Table 9.2:	Health risks of pharmaceutical residues in the water cycle and their epidemiological evidence.....	67
Table 10.1:	Types of wastewater reuse .....	70
Table 10.2:	Water reuse plants compilation from <www.vatechwabag.com>.....	71
Table 11.1:	Reduction (in %) of anthropogenic parameters at the surface water treatment plant Tegel, AAA acetylaminoantipyrine, FAA formylaminoantipyrine, AMDOPH 1-acetyl-1-methyl-2-dimethyl-oxamoyl-2-phenylhydrazide.....	77
Table 12.1:	Concentration (µg/L) of pharmaceuticals in the Braunschweig WWTP influent and effluent and in selected wells in the irrigation area. Median values of 4 sampling campaigns .....	81

## **Argumentation and Summarizing Discussion**

### **Intention of this Issue of DWA-Topics**

This issue of DWA-Topics shows possible risk potentials, possible actions and the demand for research in order to be able to avoid discharge of anthropogenic trace pollutants to the aquatic environment. Also it describes loopholes in national and European laws, such as the European Water Framework Directive. The focus is on human pharmaceuticals in place of the large variety of trace pollutants.

Various precautionary measures are recommended to avoid risks for humans and animals. If these measures are realized, pollution of the water cycle from wastewater to drinking water will be reduced. Suggested measures cover pollutant reduction at the source up to wastewater treatment processes and drinking water production.

Below, the following questions will be discussed and answered as far as possible:

- Are there any risks for humans and animals due to anthropogenic trace pollutants in the urban water cycle?
- Do regulations of the European Water Framework Directive, the European Groundwater Directive and the Drinking Water Ordinance suffice to protect mankind and environment from anthropogenic pollutants?
- Which measures can possibly be taken at discharge sources, in wastewater treatment and drinking water production?

### **Concluding Discussion and Requirements for Politics, Science and Associations**

#### **Are there any risks for humans and animals due to anthropogenic trace pollutants in the urban water cycle?**

In regard to current risk assessment criteria, none of the substances detected in water (groundwaters, drinking waters) posed a health risk for humans. However, data availability is more than unsatisfactory, since a complete health risk assessment of pharmaceuticals and their degradation products found in the water cycle is only possible in very few cases. Prioritization of substances, which need to be assessed completely, seems inevitable on the basis of exposure data and effects.

From the point of view of human toxicology, so far four toxicologically relevant effect groups have been identified, the presence of which is always undesired in regard to health: (a) substances with hormone effect potential, (b) substances with genotoxic effects (e. g. cytostatics), (c) substances with immunotoxic effects and (d) substances with antiinfective effects (e. g. antibiotics).

As long as data supply is incomplete, the so-called health based precautionary value (HPV) for non-genotoxic substances developed by the Federal Environmental Agency in Germany (UBA) is used for non-assessable or only partially assessable substances present in drinking water. This concept regards a concentration of non-genotoxic or hardly genotoxic substances below the HPV<sub>1</sub> of 0.1 µg/L as safe in regard to health at life-long exposure. For highly genotoxic substances, only values below the HPV<sub>2</sub> of 0.01 µg/L can be accepted due to their high toxicological relevance. Only if values are permanently below both these precautionary values, a sufficient safety margin to strictly toxicologically derived values can be expected for a complete assessment at a later point.

From the point of view of ecotoxicology, so far investigation of the water cycle is limited to the assessment of individual chemical substances and does include substance mixtures only in rare cases. It also hardly considers the occurrence of microbial contaminants, which of course can also influence ecosystems. These facts must be evaluated taking into regard their pathogenicity and the development of multi-resistances against antibiotics.